319 related articles for article (PubMed ID: 32587099)
1. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
Qian Y; Markowitz JS
Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
[TBL] [Abstract][Full Text] [Related]
6. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
7. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM; Cimino NM
Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
9. Effects of cannabidiol and Δ
Smith SA; Le GH; Teopiz KM; Kwan ATH; Rhee TG; Ho RC; Wu J; Cao B; Ceban F; McIntyre RS
Drug Metab Rev; 2024; 56(2):164-174. PubMed ID: 38655747
[TBL] [Abstract][Full Text] [Related]
10. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
Cherniakov I; Izgelov D; Domb AJ; Hoffman A
Eur J Pharm Sci; 2017 Nov; 109():21-30. PubMed ID: 28736128
[TBL] [Abstract][Full Text] [Related]
11. Characterization of cannabidiol-mediated cytochrome P450 inactivation.
Bornheim LM; Everhart ET; Li J; Correia MA
Biochem Pharmacol; 1993 Mar; 45(6):1323-31. PubMed ID: 8466552
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Qian Y; Wang X; Markowitz JS
Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Enzymes Relevant to the Disposition of (-)-∆
Patilea-Vrana GI; Anoshchenko O; Unadkat JD
Drug Metab Dispos; 2019 Mar; 47(3):249-256. PubMed ID: 30567877
[TBL] [Abstract][Full Text] [Related]
14. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S; Koeda K; Kushihara M; Hada Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
[TBL] [Abstract][Full Text] [Related]
15. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol.
Bornheim LM; Everhart ET; Li J; Correia MA
Biochem Pharmacol; 1994 Jul; 48(1):161-71. PubMed ID: 8043019
[TBL] [Abstract][Full Text] [Related]
16. Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.
Herdegen T; Cascorbi I
Dtsch Arztebl Int; 2023 Dec; 120(49):833-840. PubMed ID: 37874128
[TBL] [Abstract][Full Text] [Related]
17. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interactions as a result of co-administering Δ
Rong C; Carmona NE; Lee YL; Ragguett RM; Pan Z; Rosenblat JD; Subramaniapillai M; Shekotikhina M; Almatham F; Alageel A; Mansur R; Ho RC; McIntyre RS
Expert Opin Drug Saf; 2018 Jan; 17(1):51-54. PubMed ID: 29082802
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
